Accessing the Oregon Frontier: The Impact of Expanding Authority for Buprenorphine to Nurse Practitioners
Institution
OHSU
Program/Major
PhD/Epidemiology
Degree
PhD
Presentation Type
Poster
Start Date
4-7-2020 2:52 PM
End Date
4-7-2020 2:57 PM
Rights
© Copyright the author(s)
IN COPYRIGHT:
http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
DISCLAIMER:
The purpose of this statement is to help the public understand how this Item may be used. When there is a (non-standard) License or contract that governs re-use of the associated Item, this statement only summarizes the effects of some of its terms. It is not a License, and should not be used to license your Work. To license your own Work, use a License offered at https://creativecommons.org/
Persistent Identifier
https://archives.pdx.edu/ds/psu/33746
Subjects
MOUD, OUD, Buprenorphine, prescribing, PDMP
Abstract
Objective: Expanding access to medications for opioid use disorder (OUD) is a critical strategy to confront the opioid crisis. In 2017, the Comprehensive Addiction and Recovery Act (CARA) expanded buprenorphine prescribing privileges to nurse practitioners (NP). The object of this study was to evaluate the effect of CARA buprenorphine prescribing for OUD in Oregon.
Study Design: Using data from Oregon’s Prescription Drug Monitoring Program, we examined the effect of CARA enactment on buprenorphine prescribing using an interrupted time series design. We quantified changes in buprenorphine use between January 1, 2016 to December 31, 2018 overall, by provider type (NP vs MD/DO), and geography (rural, urban, frontier).
Results: Post CARA, the trend in buprenorphine use increased by 211 prescriptions per month (p=0.05). The percent attributed to waivered NPs increased by 0.7% per month (p
Conclusions: Buprenorphine dispensing rates in Oregon increased significantly following CARA implementation. The impact of adding NPs as authorized prescribers has enhanced access to buprenorphine prescriptions in rural and sparsely populated areas of the state where such patients were previously underserved.
Accessing the Oregon Frontier: The Impact of Expanding Authority for Buprenorphine to Nurse Practitioners
Objective: Expanding access to medications for opioid use disorder (OUD) is a critical strategy to confront the opioid crisis. In 2017, the Comprehensive Addiction and Recovery Act (CARA) expanded buprenorphine prescribing privileges to nurse practitioners (NP). The object of this study was to evaluate the effect of CARA buprenorphine prescribing for OUD in Oregon.
Study Design: Using data from Oregon’s Prescription Drug Monitoring Program, we examined the effect of CARA enactment on buprenorphine prescribing using an interrupted time series design. We quantified changes in buprenorphine use between January 1, 2016 to December 31, 2018 overall, by provider type (NP vs MD/DO), and geography (rural, urban, frontier).
Results: Post CARA, the trend in buprenorphine use increased by 211 prescriptions per month (p=0.05). The percent attributed to waivered NPs increased by 0.7% per month (p
Conclusions: Buprenorphine dispensing rates in Oregon increased significantly following CARA implementation. The impact of adding NPs as authorized prescribers has enhanced access to buprenorphine prescriptions in rural and sparsely populated areas of the state where such patients were previously underserved.